N3-Lys-Amyloid Beta 1-42 Peptide is derived from the amyloid-beta sequence generated from human amyloid-beta precursor protein (APP). The canonical Aβ region is publicly curated within human APP UniProtKB entry P05067. Amyloid Beta Research Peptides Amyloid-beta peptides are central research reagents in studies of peptide aggregation, amyloid fibril formation, membrane interactions, proteolytic processing, antibody recognition, and analytical assay development. Aβ1-40 and Aβ1-42 are the two most widely studied C-terminal forms. Aβ1-42 contains two additional C-terminal residues relative to Aβ1-40 and generally displays stronger aggregation propensity under many experimental conditions. Sequence, concentration, solvent history, pre-treatment, and incubation conditions can all strongly affect aggregation state. Aβ1-42 Parent Sequence DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIA N-Terminal Azido-Lysine Handle LT8744 contains the complete Aβ1-42 sequence preceded by an added Lys(N3) residue. The azide functionality provides a site for click-chemistry conjugation while leaving all 42 residues of the canonical Aβ sequence present in the construct. The added lysine is not part of native Aβ1-42 and can influence physicochemical behavior; application-specific validation is recommended. Potential Research Applications - Amyloid aggregation studies
- LC-MS analytical methods
- Antibody binding assays
- Peptide-protein interaction studies
- Fluorescent or chemical conjugation
- Reference-standard development
For aggregation-sensitive studies, peptide handling and pre-treatment procedures should be standardized across experiments. References UniProt Consortium APP - Amyloid-beta precursor protein - Homo sapiens. UniProtKB P05067. Public source / publication Related LifeTein Services Custom Peptide Synthesis Fluorescent Peptide Labeling Peptide Click Chemistry and Conjugation Peptide Carrier Protein Conjugation Research Use Only. Not for human, diagnostic, clinical, or therapeutic use. |